Physician profile
Eric M Karlin
NPI 1356579486
$521,759.84
in general payments reported to CMS, 2019-2025
43 companies · $95K in 2025
The $95K reported for 2025 was more than what 98% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $31K · 2021: $85K · 2022: $87K · 2023: $72K · 2024: $105K · 2025: $95K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $204K · Consulting Fee: $30K · Food and Beverage: $21K · Travel and Lodging: $16K · Education: $60.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $204,061.50 |
| Consulting Fee | $30,244.94 |
| Food and Beverage | $21,232.89 |
| Travel and Lodging | $15,793.82 |
| Education | $60.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $233,661.57 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Optinose US, INC. | $177,000.25 | 2019-2025 | |
| Grifols USA, LLC | $53,483.35 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $14,112.05 | 2022-2025 | |
| Amgen INC. | $8,945.28 | 2021-2025 | Tezspire, Actimmune, Otezla |
| Genentech USA, INC. | $6,596.95 | 2019-2025 | Xolair |
| Genzyme Corporation | $6,128.98 | 2019-2025 | |
| Regeneron Pharmaceuticals, INC. | $3,390.86 | 2019-2024 | Dupixent |
| Glaxosmithkline, LLC. | $2,463.09 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Grifols Shared Services North America, INC. | $2,447.94 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Csl Behring | $1,833.72 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Janssen Global Services, LLC | $1,760.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $1,690.14 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $1,241.52 | 2020-2025 | Takhzyro, Cuvitru, Hyqvia |
| Abbvie INC. | $1,166.76 | 2022-2024 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $802.04 | 2019-2025 | |
| Adma Biomanufacturing LLC | $572.44 | 2024-2025 | |
| Kaleo, INC. | $542.43 | 2019-2024 | Auvi-Q |
| Ionis Pharmaceuticals, INC. | $456.07 | 2025 | Dawnzera |
| Biocryst US Sales Co., LLC | $426.79 | 2021-2024 | Orladeyo |
| Blueprint Medicines Corporation | $373.25 | 2023-2025 | Ayvakit |
| Genentech, INC. | $319.03 | 2023-2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $298.27 | 2025 | Neffy |
| Incyte Corporation | $285.01 | 2021-2025 | Opzelura |
| Pharming Healthcare, INC. | $259.55 | 2020-2025 | Ruconest |
| Galderma Laboratories, L.P. | $201.98 | 2025 | Nemluvio |
| Horizon Therapeutics Plc | $195.28 | 2020-2023 | Actimmune |
| Shire North American Group INC | $173.89 | 2019 | |
| Lilly USA, LLC | $156.49 | 2025 | Ebglyss, Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.85 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $148.83 | 2020-2022 | |
| Leo Pharma INC. | $68.21 | 2022 | |
| Aimmune Therapeutics, INC. | $64.23 | 2021-2022 | |
| Octapharma USA, INC. | $59.66 | 2022-2024 | Cutaquig |
| Azurity Pharmaceuticals, INC. | $49.19 | 2025 | Alvesco |
| Biocryst Pharmaceuticals, INC. | $42.44 | 2020 | |
| Organon LLC | $38.73 | 2025 | Vtama |
| Alk-Abello, INC | $35.84 | 2019 | |
| Hikma Pharmaceuticals USA | $33.77 | 2022-2023 | Ryaltris |
| Seqirus USA INC | $29.19 | 2023-2025 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Paratek Pharmaceuticals, INC. | $23.86 | 2025 | Xhance |
| Merck Sharp & Dohme LLC | $17.56 | 2023 | |
| Sanofi-Aventis U.S. LLC | $14.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Karlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.